Granules India successfully closes acquisition of Swiss based CDMO Senn Chemicals

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said, "The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organization. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialized CDMO capabilities, we are wellpositioned to deliver high-quality, next-generation treatments. Senn’s specialized expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space."

The acquisition will enable Granules to accelerate development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in antidiabetic, anti-obesity, and other next-generation therapeutic areas. Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned. This transaction also marks Granules’ foray into the CDMO space.

"The acquisition enhances Granules’ global footprint and provides access to a regulated market client base and highly skilled scientific talent in Europe," the release stated.

Stifel Nicolaus India served as the exclusive financial advisor to Granules India on the transaction. Loyens & Loeff acted as legal advisor, Deloitte as financial and tax advisor, providing financial and tax due diligence services and Kroll provided valuation advisory services for the transaction.